E-Book

E-Book 3rd Congress

  • PROTACs in the management of breast cancer
  • Mona Asna Ashari,1,* Mohammad Saleh Safari,2
    1. Paramedicine Faculty, Tehran Medical sciences, Islamic Azad University, Tehran, Iran
    2. Young Research and Elites Club, Science and Research Branch, Islamic Azad University, Tehran, Iran.


  • Introduction: Cancer treatments with targeted therapy have received much attention due to their low levels of toxicity and high selectivity. Proteolysis targeting chimeras (PROTACs) have attracted special attention in the development of cancer therapies due to their unique mechanism of action, their ability to target undruggable proteins and their focused target engagement. PROTACs selectively degrade the target protein through the ubiquitin-proteasome system, which describes a different function compared to conventional small molecule inhibitors or even antibodies. Among the types of cancer, breast cancer is the most common cancer in women, and drug resistance has been seen in the treatment of this cancer, so PROTACs can be a new method in the treatment of this cancer.
  • Methods: This study is a review study by searching scientific databases such as Scopus, PubMed, Google Scholar, and Embase from 2016 to 2023 by using the keywords Breast cancer, PROTAC, resistance, 21 articles related to inclusion criteria were extracted and then analyzed.
  • Results: The results indicated that with genetic changes and overexpression of genes that are resistant to treatment and suppress the response of the immune system, drug resistance is created against the usual treatments of breast cancer, and since the progression of ARV-471 (PROTAC for BC) into the clinical stages, research has shifted toward protein inhibitors that target breast cancer.
  • Conclusion: In the present study, highlights an overview of PROTACs in breast cancer and their superiority over conventional inhibitors. In addition, we touch different targets for PROTACs in breast cancer, including estrogen receptor (ER) and other critical oncoproteins, and discuss the future prospects and challenges in this context.
  • Keywords: Breast cancer, PROTAC, resistance.